Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Emerging molecular diagnostics are redefining how clinicians evaluate cytopenias, bone marrow failure, and hereditary anemias, enabling more accurate diagnoses and better-informed treatment decisions.
Emerging molecular diagnostics are redefining how clinicians evaluate cytopenias, bone marrow failure, and hereditary anemias, enabling more accurate diagnoses and better-informed treatment decisions.
In a panel presentation at ASH 2025, experts highlight current data on complement activity, B-cell–directed therapies, and personalized approaches for difficult-to-treat immune cytopenias.
In a panel presentation at ASH 2025, experts highlight current data on complement activity, B-cell–directed therapies, and personalized approaches for difficult-to-treat immune cytopenias.
Experts spotlight new evidence shaping the prevention and treatment of cancer-associated thrombosis, with growing emphasis on direct oral anticoagulants (DOACs) and risk-guided care.
Experts spotlight new evidence shaping the prevention and treatment of cancer-associated thrombosis, with growing emphasis on direct oral anticoagulants (DOACs) and risk-guided care.
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
Earlier-line use of ciltacabtagene autoleucel (cilta-cel) is linked to stronger immune fitness and longer progression-free survival in multiple myeloma, according to new correlative biomarker analyses from CARTITUDE-1 and CARTITUDE-4.
Earlier-line use of ciltacabtagene autoleucel (cilta-cel) is linked to stronger immune fitness and longer progression-free survival in multiple myeloma, according to new correlative biomarker analyses from CARTITUDE-1 and CARTITUDE-4.
A new analysis presented at ASH 2025 identifies high tumor mutational burden as a clinically meaningful biomarker of negative outcomes following CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL). Using...
A new analysis presented at ASH 2025 identifies high tumor mutational burden as a clinically meaningful biomarker of negative outcomes following CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL). Using...
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
The American Society of Hematology Annual Meeting & Exposition was held in San Diego, California, December 9-12, 2023. Read our selection of online news coverage of the conference that features the discoveries, emerging therapies, and...
The American Society of Hematology Annual Meeting & Exposition was held in San Diego, California, December 9-12, 2023. Read our selection of online news coverage of the conference that features the discoveries, emerging therapies, and...
Pallawi Torka, MD, and colleagues investigated whether a geriatric assessment or its component measures can predict toxicity in older adults with non-Hodgkin lymphoma.
Pallawi Torka, MD, and colleagues investigated whether a geriatric assessment or its component measures can predict toxicity in older adults with non-Hodgkin lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed refractory multiple myeloma who have had at least four prior lines of therapy.
Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed refractory multiple myeloma who have had at least four prior lines of therapy.
Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...
Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...
Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.
Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.
Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Jennifer Brown, MD, PhD, found that zanubrutinib may provide further efficacy, safety, and improved progression-free survival compared to ibrutinib among patients with relapsed/refractory CLL and SLL.
Jennifer Brown, MD, PhD, found that zanubrutinib may provide further efficacy, safety, and improved progression-free survival compared to ibrutinib among patients with relapsed/refractory CLL and SLL.
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.
At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.
At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...
At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...
In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...
In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Michele Muir, PharmD, discusses results from a study evaluating the effectiveness and safety of generic imatinib compared to branded imatinib for patients with CML in real-world clinical practice.
Michele Muir, PharmD, discusses results from a study evaluating the effectiveness and safety of generic imatinib compared to branded imatinib for patients with CML in real-world clinical practice.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Kerry Rogers, MD, discusses her study on real world-data regarding the cost of treatment for tumor lysis syndrome in patients with CLL and SLL, presented at the 2021 ASH Annual Meeting and Exposition.
Kerry Rogers, MD, discusses her study on real world-data regarding the cost of treatment for tumor lysis syndrome in patients with CLL and SLL, presented at the 2021 ASH Annual Meeting and Exposition.
Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.
Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.
Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
